Compare Moderna, Inc. (MRNA) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Paychex, Inc. — how do they compare? Moderna, Inc. trades at $63.87 (market cap $24.18B), while Paychex, Inc. trades at $119.69 (market cap $43.14B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays a 3.92% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PAYX | |
|---|---|---|
Market Cap | $24.18B | $43.14B |
Sector | Health | Industrials |
52-Week High | $81.80 | $140.81 |
52-Week Low | $22.36 | $85.57 |
Enterprise Value | $20.33B | $46.63B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Paychex (PAYX) trades at $119.93, down 1.03% today, with a bullish technical outlook and strong profitability. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.33. The company maintains robust margins, including a 27.03% net income margin, and pays a steady dividend of $1.19 quarterly. Cash flow trends indicate operational strength, though 2025 saw significant investing outflows.
The stock presents a mixed outlook: solid fundamentals and dividend appeal are offset by a consensus 'Hold' rating and a price target below the current level. Risks include high valuation multiples and potential economic sensitivity for small business clients. Upside depends on sustained earnings growth and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
